Table 1. Patient characteristics.
| Variable | Intention to treat population | QOL population | Intention to treat population vs. QOL population | |||||
|---|---|---|---|---|---|---|---|---|
| Non-HIPEC (n=92) | HIPEC (n=92) | p-value | Non-HIPEC (n=82) | HIPEC (n=83) | p-value | p-value | ||
| Age (yr) | 0.336* | 0.447* | 0.908* | |||||
| Mean ± SD | 54.0±9.7 | 53.1±9.7 | 54.0±10.1 | 53.2±9.6 | ||||
| Median (Min–Max) | 53.5 (25.0–72.0) | 52.0 (28.0–74.0) | 53.5 (25.0–72.0) | 52.0 (28.0–74.0) | ||||
| Stage | 0.175† | 0.133† | 0.775† | |||||
| III | 51 (55.4) | 60 (65.2) | 46 (56.1) | 56 (67.5) | ||||
| IV | 41 (44.6) | 32 (34.8) | 36 (43.9) | 27 (32.5) | ||||
| Histology | 0.228‡ | 0.202‡ | 1.000‡ | |||||
| Serous | 79 (85.9) | 85 (92.4) | 70 (85.4) | 76 (91.6) | ||||
| Endometrioid | 5 (5.4) | 3 (3.3) | 5 (6.1) | 3 (3.6) | ||||
| Clear cell | 4 (4.4) | 0 (0) | 4 (4.9) | 0 (0) | ||||
| Others | 4 (4.4) | 4 (4.3) | 3 (3.7) | 4 (4.8) | ||||
| Neoadjuvant chemotherapy | 0.179† | 0.483† | 0.561† | |||||
| No | 49 (53.3) | 58 (63.0) | 48 (58.5) | 53 (63.9) | ||||
| Yes | 43 (46.7) | 34 (37.0) | 34 (41.5) | 30 (36.1) | ||||
| Bowel resection | 0.384† | 0.447† | 0.651† | |||||
| No | 24 (26.1) | 19 (20.7) | 23 (28.0) | 19 (22.9) | ||||
| Yes | 68 (73.9) | 73 (79.4) | 59 (72.0) | 64 (77.1) | ||||
| ECOG performance | 0.294† | 0.129† | 0.337† | |||||
| 0 | 51 (55.4) | 58 (63.0) | 48 (58.5) | 58 (69.9) | ||||
| 1 | 41 (44.6) | 34 (37.0) | 34 (41.5) | 25 (30.1) | ||||
ECOG, European Cooperative Oncology Group; HIPEC, hyperthermic intraperitoneal chemotherapy; QOL, quality of life; SD, standard deviation.
*Wilcoxon rank sum test; †Chi-squared test; ‡Fisher’s exact test.